589 related articles for article (PubMed ID: 26126806)
1. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
2. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
5. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
6. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
[TBL] [Abstract][Full Text] [Related]
7. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
[No Abstract] [Full Text] [Related]
8. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
9. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Webster AC; Lee VW; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD004290. PubMed ID: 16625599
[TBL] [Abstract][Full Text] [Related]
10. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
11. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Webster AC; Lee VW; Chapman JR; Craig JC
Transplantation; 2006 May; 81(9):1234-48. PubMed ID: 16699448
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
13. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
[TBL] [Abstract][Full Text] [Related]
14. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
16. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Grigg SE; Sarri GL; Gow PJ; Yeomans ND
Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
[TBL] [Abstract][Full Text] [Related]
17. mTOR Inhibition and Clinical Transplantation: Liver.
Nashan B
Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
[TBL] [Abstract][Full Text] [Related]
19. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
Front Immunol; 2021; 12():663602. PubMed ID: 34539621
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]